IDEXX Laboratories (NASDAQ:IDXX) Announces Earnings Results, Beats Expectations By $0.25 EPS

IDEXX Laboratories (NASDAQ:IDXX) announced its quarterly earnings data on Monday. The company reported $3.96 EPS for the quarter, beating analysts’ consensus estimates of $3.71 by $0.25, FiscalAI reports. The firm had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.19 billion. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The business’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period last year, the company earned $3.22 EPS.

Here are the key takeaways from IDEXX Laboratories’ conference call:

• IDEXX raised its 2026 outlook, increasing revenue guidance to $4.741 billion–$4.767 billion and EPS guidance to $14.96–$15.16. The company now expects 9.3%–10% organic revenue growth and 15%–16% comparable EPS growth.
• Third-quarter performance was strong, with 10% organic revenue growth, 11% organic growth in companion-animal diagnostics recurring revenue, and 22% comparable EPS growth. Growth was volume-led and supported by international expansion, new customers, premium instrument placements, and increased diagnostic utilization.
• Innovation momentum remains a major growth driver. IDEXX placed 5,780 premium instruments, including 1,904 inVue Dx analyzers, while expanding inVue Dx FNA availability, the Cancer Dx panel, Catalyst proBNP, and software capabilities.
• The company said inVue Dx placements are on track to exceed its 2026 target of 5,500 and its five-year goal of 20,000, with strong international demand and additional upside from FNA and future menu expansion.
• U.S. same-store clinical visits declined an estimated 1.8%, with muted puppy and kitten adoption trends and ongoing macroeconomic pressure. The CoVet acquisition is expected to dilute 2026 operating margin by approximately 30 basis points and EPS by about $0.13 per share in the near term, although management expects margin expansion as integration progresses.

IDEXX Laboratories Stock Up 0.8%

IDXX stock opened at $676.04 on Friday. The company has a quick ratio of 0.87, a current ratio of 1.19 and a debt-to-equity ratio of 0.16. IDEXX Laboratories has a twelve month low of $500.61 and a twelve month high of $769.98. The business’s 50-day moving average price is $546.75 and its 200-day moving average price is $573.35. The stock has a market cap of $53.26 billion, a P/E ratio of 45.59 and a beta of 1.55.

Insiders Place Their Bets

In related news, Director Daniel M. Junius sold 1,200 shares of the company’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $704.07, for a total transaction of $844,884.00. Following the completion of the sale, the director directly owned 2,361 shares in the company, valued at $1,662,309.27. This represents a 33.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Jonathan Mazelsky sold 25,140 shares of the firm’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $703.19, for a total transaction of $17,678,196.60. Following the completion of the transaction, the insider directly owned 83,803 shares of the company’s stock, valued at approximately $58,929,431.57. This represents a 23.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 41,428 shares of company stock worth $28,567,934. Insiders own 0.79% of the company’s stock.

Trending Headlines about IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: A Zacks article says IDEXX’s above-average financial growth could help it outperform, bolstering the growth-investment case. Zacks growth-investor article
• Positive Sentiment: Morgan Stanley raised its price target on IDXX, a potentially supportive analyst signal; the available report does not state the revised target. Morgan Stanley price-target report
• Positive Sentiment: Recent quarterly results beat expectations: IDEXX reported EPS of $3.96 versus $3.71 expected and revenue of $1.21 billion versus $1.19 billion expected. Revenue grew 9.9% year over year. IDEXX quarterly results analysis
• Negative Sentiment: Four directors and executives sold a combined 39,225 shares on November 4, worth about $27.4 million, and each reduced their reported holdings. The sales may weigh on sentiment, although insider transactions do not by themselves indicate a negative company outlook. Insider-trading report
• Negative Sentiment: A Seeking Alpha article downgraded IDXX, arguing the shares are expensive despite the company’s business quality. Valuation concerns could temper the positive effect of earnings growth. IDEXX valuation downgrade

Wall Street Analyst Weigh In

Several research firms have weighed in on IDXX. UBS Group upped their price objective on shares of IDEXX Laboratories from $627.00 to $700.00 and gave the stock a “neutral” rating in a report on Tuesday. Morgan Stanley boosted their target price on IDEXX Laboratories from $805.00 to $810.00 and gave the company an “overweight” rating in a research note on Tuesday. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. BTIG Research dropped coverage on shares of IDEXX Laboratories in a research report on Friday, October 30th. They issued a “buy” rating for the company. Finally, KeyCorp assumed coverage on shares of IDEXX Laboratories in a research report on Monday, October 12th. They set a “sector weight” rating on the stock. Seven investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $719.55.

IDEXX Laboratories Company Profile

IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices.

The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.